Synchrony Financial (NYSE:SYF) has its shares plummet by -10.93% or $4.03 from its all-time high of $36.87, with SYF attaining that price back on July 25, 2019. The drop in the price of the shares saw it stand at $32.84 per share. SYF has been trading at a low of $21.77 over the past one year but it surged by 50.85% or $11.07 to reach the $32.84 mark. Following the massive rise in stock price, SYF received more attention from investors and analysts. On Wednesday, the stock dipped by -5.31%, which caused investors and analysts to worry about it. Following the plunge in price, the SYF beta stands at 1.15, implying that its volatility level has gone up by -0.15 ahead of the general market. A look at the stock’s 200-day moving average shows that it is 5.49% above while its 50-day moving average shows that it is currently -6.01% below. Compared to 2.24% average daily volatility of past month, the stock’s average volatility for this week has increased by 0.84 as the volatility level currently stands at 3.08%.
Over the past seven days, the stock has witnessed a price dip by -4.56%. This massive drop in stock price has caught the attention of both investors and market traders. The stock has performed excellently over the past 52 weeks, rising by 12.5% during that time frame and is now up by 39.98% since this point this year. SYF has fell by -8.85% over the past 30 days, with its equity price losing% of its value over the past ninety days. These figures add up to see the stock record a growth of 6.73% over the past six months.
Market analysts from research firms still remain bullish about the short-term performance of SYF. Most of them are of the view that the stock would be able to reach $40.55 over the next 12 months. If that happens, then the stock would witness a 23.48% rise in its price and that would see the stock’s market cap hit an astonishing $28 Billion. Analysts view this stock as a bullish at the moment as its average rating is 1.9. According to Reuters, most of the 18 analysts covering the stock at the moment believe it is a Buy. 5 of them rated SYF as a Hold while 13 of them either rated it as a Buy or a Strong Buy. However, 0 of them advised investors to sell the stock if they have it or shouldn’t buy it if they don’t possess any.
The stock’s technical analysis reveals that its 14-day Relative Strength Index (RSI) is currently in a neutral position as it was able to attain 36.29 points. Over the past three months, the trading volume has jumped massively, by roughly ????118.45%???, with the trading volume now standing at 6491906 shares. The increase of 1261906 shares in trading volume shows that traders and investors have shown more interest in the stock over the past few weeks. During that trading session, the average trading volume of SYF was 5230000 shares, which is more than 1.24 times higher than its usual trading volume.
Biogen Inc. has seen its stock (NASDAQ:BIIB) plunge by $-6.51 or -2.79% to currently trade at $226.72. This fall in the price of the stock has seen it establish a strong support at $224.96 a share. If the stock price is to drop below that support level, then it would be followed by a bearish trend. A slip below $223.2 would be bad for BIIB as it would mean that the stock has lost 1.55% of its value. The stock going in the opposite direction and breaking past the resistance point to reach $229.52 would see it surge even higher. BIIB would attempt to surge past the upward resistance point which is set at $232.33 a share. BIIB has an average volatility of 2.29% over the past 30 days, while it has gained 4.68% of its value compared to its 52-weeks low point which stands at $216.12 on Mar 25, 2019. In the same breath, BIIB has lost 0.32% compared to its 52-weeks high point which currently stands at $226 a share reached on Oct 01, 2018.
Analysts have set a 1-year price target for this stock, with most of them expecting it to reach $257.09/share over the next 12 months. If that happens, then BIIB would witness a 13.4% rise from its current price. The price of the stock has been moving between $226 and $230.565. Not all analysts believe it would hit that target though, as some of them expect it to trade lower, as low as $203 per share. In the same breath, one analyst believes that the stock is set to soar even higher than expected, as the price target was set at $320.
The stock has an average rating of 2.9 which means that it has been rated as a Hold by most analysts. The stock is being covered by 30 analysts who gave a consensus recommendation of 2.9 which implies that it is currently in a neutral situation. Reuters looked into analysts covering Biogen Inc., and 24 of them believe that the stock is a Hold at the moment. 6 of the analysts rated it as a Buy or a Strong Buy while the remaining analysts (2) rated it as a sell at the moment.